跳转到主要内容


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
快速连接

白皮书

Product Alert – Tucatinib API

Product Alert – Tucatinib API

Tucatinib is a small molecule tyrosine kinase inhibitor that selectively targets human epidermal growth factor receptor 2 (HER2). HER2 is a transmembrane receptor that is overexpressed in some types of cancer, including breast cancer.

Tucatinib binds to the intracellular domain of HER2, which blocks the activation of downstream signalling pathways that promote cell growth and proliferation. Specifically, tucatinib inhibits the phosphorylation of HER2 and downstream proteins such as AKT and ERK.

Dr. Reddy's API Offering

  • Improved route of synthesis (ROS) and process, cost-effective convergent synthesis (Dr. Reddy's filed provisional patent application).
  • We plan to offer Form B Hemithanolate solvate and Amorphous form (Lab samples for the same are available).
  • Reliable KSM suppliers added to ensure timely deliveries and adherence to stringent specifications.
  • Planning adequate capacity to supply development quantity in a short lead time.

To know more about our API offerings, please read the Tech sheet on Tucatinib API by filling the contact form below.

Explore other Whitepapers:

Know More

Download Now

请填写下面的联系表以查看白皮书

给我们发电子邮件: api@drreddys.com | +91 40 49002222

免责声明

本目錄中的任何信息(包括對任何產品或服務的任何引用)均不構成銷售要約,或被解釋為代表銷售要約。受有效專利保護的產品不提供或供應用於商業用途。但是,只要存在此類監管豁免,就可以出於監管提交的目的提供此類產品的研究數量。買方應對各自市場的專利方案進行獨立評估,並承擔所有與專利相關的責任。在印度受有效專利保護的產品不可用於商業用途,但可用於第 107A 節。